Compare GMEX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMEX | VRAX |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Australia | United Kingdom |
| Employees | 16 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.6M |
| IPO Year | 2023 | 2021 |
| Metric | GMEX | VRAX |
|---|---|---|
| Price | $0.79 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 1.8M | ★ 31.8M |
| Earning Date | 04-17-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.10 |
| 52 Week High | $2.50 | $1.14 |
| Indicator | GMEX | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 45.91 |
| Support Level | $0.35 | $0.11 |
| Resistance Level | $1.25 | $0.18 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 3.96 | 8.94 |
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.